ReviewCancer chemotherapy and pharmacology2026
Antibody-drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges.
Review in Cancer chemotherapy and pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Enzyme-mediated remodeling of the extracellular matrix and glycocalyx to enhance immunotherapy in solid tumors.Bioengineering & translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, largely because of tumor heterogeneity, therapeutic resistance, and the limited efficacy of existing targeted therapies in advanced disease. Antibody-drug conjugates (ADCs) have emerged as a promising class of targeted anticancer therapeutics that combine the specificity of monoclonal antibodies with the cytotoxic potency of highly active payloads, thereby enabling selective tumor cell killing while minimizing systemic toxicity. Although ADCs have demonstrated substantial clinical success in several solid and hematological malignancies, their translation to CRC has been relatively limited, underscoring the need for a focused evaluation of CRC-specific ADC development. This review provides a comprehensive and critical overview of recent advances in ADC design and preclinical development for CRC, with emphasis on molecular architecture, linker-payload chemistry, antigen selection, and pharmacological mechanisms of action. Key components of ADCs, including antibody formats, cleavable and noncleavable linkers, and cytotoxic payload classes such as auristatins, maytansinoids, duocarmycins, and topoisomerase inhibitors, are discussed in the context of optimizing the therapeutic index and tumor selectivity. Mechanistic aspects of ADC activity, including antigen-mediated internalization, intracellular trafficking, payload release, and the bystander effect, are highlighted for their relevance to heterogeneous CRC tumors. This review systematically summarizes emerging preclinical ADC candidates targeting CRC-associated antigens, including EGFR, CEACAM5, c-Met, RON, DDR1, GPR56, LGR5, Claudin-2, and CD98hc. Finally, key translational challenges-including antigen heterogeneity, limited internalization, and off-target toxicity-are discussed alongside future perspectives emphasizing biomarker-driven patient selection and rational ADC design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.